ClinicalTrials.gg
CompletedNCT00642499Updated Apr 2, 2008

Dronabinol Versus Placebo in Treatment and Prevention of Highly Active Anti-Retroviral Therapy (HAART)-Related Nausea and Vomiting

A Phase 2 interventional study of Dronabinol and Placebo in Highly Active Antiretroviral Therapy (HAART)-Related Nausea and Vomiting and HIV Infections, sponsored by Solvay Pharmaceuticals. Completed at 36 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2008-04-02.

Sponsored by Solvay Pharmaceuticals (part of Abbott) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
103
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 286 studies in Vomiting with a site in United States — 26 open to participants now, 29 under way, 5 of them phase 3. Vomiting · United States.

Enrollment
111th of 256
103 · median 89
Started
2003
with 8 others
Phase 2
57 of 286
2 open now
Registered
68th of 286
by date

Among the 286 studies in Vomiting with a site in United States, this one is the 111th largest by enrollment of the 256 interventional ones that give a count, is one of 9 that started in 2003, is one of 57 in phase 2, and was the 68th registered.

Vomiting

794 studies on the registry are indexed under Vomiting; 99 are open to participants now.

Browse Vomiting studies →

Open to participants now

26 of the 286 studies in Vomiting with a site in United States are open now. Recruiting first, the newest first:

21 more — sign in →

All 26 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 56 Vomiting studies recruiting now, 26 (46%) set no upper age limit and 24 (43%) stop at 75 or younger; 10 take children under 18; 17 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 286 studies in Vomiting with a site in United States, or all of them as a file.
02

Study summary

The primary purpose of this study is to determine if dronabinol is effective in preventing or treating nausea caused by HAART (highly active anti-retroviral therapy) in HIV and AIDS patients

03

Conditions studied

  • Highly Active Antiretroviral Therapy (HAART)-Related Nausea and Vomiting
  • HIV Infections

Keywords

  • HIV
  • AIDS
  • nausea
  • vomiting
  • HAART
  • Treatment Experienced
  • HIV Infections
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adherence to prior or current HAART was or is being compromised, or HAART was discontinued/interrupted due to nausea/vomiting; or beginning HAART or switching from a regimen at the time of screening for this study that did not produce significant nausea and/or vomiting to a regimen with zidovudine or a protease inhibitor (with or without low dose ritonavir).

Exclusion criteria

Exclusion Criteria:

  • Subjects with recent (within 30 days of randomization) or current opportunistic infection or neoplasm characteristic of AIDS (Category C of the CDC Classification System for -1 infection, 1993 Revised Version).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
103 participants (actual)

Study arms

  • Experimental
    1

    Drug: Dronabinol

  • Placebo comparator
    2

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. The absence of nausea as indicated by a visual analog scale (VAS) score < 5 mm

    Time frame: 2 weeks

Secondary outcomes

  1. Number of episodes vomiting/retching

    Time frame: 2 weeks

  2. Duration of nausea, vomiting/retching

    Time frame: 2 weeks

  3. Intensity of nausea by VAS

    Time frame: 2 weeks

  4. Appetite stimulation by VAS

    Time frame: 2 weeks

07

Study locations

36 sites
  • Site 911
    Bakersfield, California, United States
  • Site 919
    Fresno, California, United States
  • Site 924
    Los Angeles, California, United States
  • Site 932
    Los Angeles, California, United States
  • Site 926
    Palm Springs, California, United States
  • Site 946
    Pasadena, California, United States
  • Site 913
    Tarzana, California, United States
  • Site 907
    Altamonte Springs, Florida, United States
  • Site 948
    Miami, Florida, United States
  • Site 951
    Miami, Florida, United States
  • Site 953
    Miami, Florida, United States
  • Site 959
    Miami, Florida, United States
  • Site 954
    N. Palm Beach, Florida, United States
  • Site 957
    Pensacola, Florida, United States
  • Site 923
    Port St. Lucie, Florida, United States
  • Site 929
    Sarasota, Florida, United States
  • Site 952
    Tallahassee, Florida, United States
  • Site 931
    Tampa, Florida, United States
  • Site 908
    Decatur, Georgia, United States
  • Site 905
    Boise, Idaho, United States
  • Site 914
    Chicago, Illinois, United States
  • Site 928
    Louisville, Kentucky, United States
  • Site 955
    Louisville, Kentucky, United States
  • Site 958
    New Orleans, Louisiana, United States
  • Site 934
    Boston, Massachusetts, United States
  • Site 915
    Springfield, Missouri, United States
  • Site 956
    Somers Point, New Jersey, United States
  • Site 921
    Albany, New York, United States
  • Site 910
    Cincinnati, Ohio, United States
  • Site 941
    Philadelphia, Pennsylvania, United States
  • Site 925
    Dallas, Texas, United States
  • Site 917
    Fort Worth, Texas, United States
  • Site 906
    Houston, Texas, United States
  • Site 942
    Houston, Texas, United States
  • Site 909
    Tacoma, Washington, United States
  • Site 927
    Vancouver, Washington, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2003, a primary completion of Apr 2005 and a completion of Apr 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2008
First posted
Mar 25, 2008
Start
Aug 2003
Primary completionActual
Apr 2005
CompletionActual
Apr 2005
Last update
Apr 2, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00642499
First posted
Mar 25, 2008
Start date
Aug 2003
Primary completion
Apr 2005
Completion
Apr 2005
Last update
Apr 2, 2008

Study contacts

Global Clinical Director Solvay
study director · Solvay Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dronabinol

Start the discussion